Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Publikáció
TYK2-Wnt5a Crosstalk in Psoriatic Arthritis: A Hypothesized Immunopharmacological Axis for Inflammation and Structural Remodelling.
2026. okt. 8.· Current drug targets· PUBMED
Publikáció
Safety, pharmacokinetics and pharmacodynamics of ICP-332, an oral TYK2 inhibitor, in healthy participants: a randomized, double-blind, placebo-controlled phase I study.
2026. okt. 7.· Frontiers in pharmacology· PUBMED
Vizsgálat
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
2026. okt. 1.· PHASE2 · RECRUITING· CTGOV
Publikáció
Pharmacodynamic analysis of TYK2 inhibition by deucravacitinib: results from the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus.
2026. aug. 27.· Annals of the rheumatic diseases· PUBMED
Publikáció
Evaluating zasocitinib as an oral therapy for moderate to severe plaque psoriasis.
2026. aug. 16.· Expert opinion on pharmacotherapy· PUBMED
Publikáció
Efficacy and safety of Janus kinase and TYK2 inhibitors in the treatment of generalized pustular psoriasis and palmoplantar pustulosis: a systematic review.
2026. aug. 10.· Immunologic research· PUBMED
Publikáció
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.
2026. aug. 7.· Annals of the rheumatic diseases· PUBMED
Publikáció
Cannabidiol as a Promising Anti-Inflammatory Agent Targeting TYK2: Molecular Docking and Dynamic Simulation Approaches for Therapeutic Applications in Multiple Sclerosis.
2026. júl. 30.· Current drug discovery technologies· PUBMED
Publikáció
Tyrosine kinase 2 inhibition by GL-V9 treats psoriasiform dermatitis via macrophage-helper T-cell modulation.
2026. júl. 24.· British journal of pharmacology· PUBMED
Publikáció
Phosphorylated TYK2 orchestrates the pathogenic program of CD4 + T cells in the development of CNS autoimmunity.
2026. júl. 10.· Journal of neuroinflammation· PUBMED
Publikáció
TYK2 signaling as a molecular bridge between cytokine storm and chronic inflammation: therapeutic implications of deucravacitinib.
2026. júl. 3.· Molecular biology reports· PUBMED
Publikáció
The Role of TYK2 Inhibitors in the Pathogenesis and Treatment of Psoriasis.
2026. júl. 1.· The Journal of clinical and aesthetic dermatology· PUBMED
Publikáció
Targeted therapies against type I interferon and TNF-alpha in cutaneous lupus erythematosus: A systematic review of randomized trials.
2026. jún. 30.· Dermatology online journal· PUBMED
Publikáció
Rethinking TYK2 P1104A: a flawed evolutionary trade-off in tuberculosis?
2026. jún. 16.· Frontiers in immunology· PUBMED
Publikáció
Kirenol, a diterpene active component from Siegesbeckia orientalis, alleviates atopic dermatitis by suppressing TYK2.
2026. jún. 3.· International immunopharmacology· PUBMED
Publikáció
[Successful treatment of lupus erythematosus tumidus (LET) with deucravacitinib in a patient with concomitant plaque psoriasis].
2026. jún. 2.· Dermatologie (Heidelberg, Germany)· PUBMED
Publikáció
Mechanisms of Differential Signal Transduction by Interferon Lambda Receptor 1 Variants.
2026. máj. 29.· Journal of innate immunity· PUBMED
Publikáció
Discovery of potential covalent TYK2 inhibitors targeting Cys736 for the treatment of psoriasis.
2026. máj. 17.· Bioorganic & medicinal chemistry· PUBMED
Publikáció
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.
2026. máj. 16.· Dermatology and therapy· PUBMED
Publikáció
Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial.
2026. máj. 12.· Annals of the rheumatic diseases· PUBMED
Publikáció
A review of the indications, safety, and efficacy of deucravacitinib: An expert consensus panel.
2026. máj. 8.· Dermatology online journal· PUBMED
Publikáció
Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition.
2026. máj. 1.· Skin therapy letter· PUBMED
Publikáció
Long noncoding RNA AFAP1-AS1 aggravates immunotherapy resistance in NSCLC by enhancing JAK2 and TYK2 translation.
2026. ápr. 24.· Journal of advanced research· PUBMED
Publikáció
Use of Oral JAK Inhibitors and a TYK2 Inhibitor in the Treatment of Psoriasis-Eczema Overlap (PsEma): A Retrospective Study.
2026. ápr. 10.· International journal of dermatology· PUBMED
Publikáció
Targeting TYK2 in Cutaneous Autoimmunity: Deucravacitinib-Induced Remission of Discoid Lupus and Psoriasis with Supportive Confocal Microscopy Findings.
2026. ápr. 9.· Dermatology and therapy· PUBMED
Publikáció
Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review.
2026. ápr. 4.· Dermatology and therapy· PUBMED
Publikáció
Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction.
2026. márc. 25.· Nature communications· PUBMED
Publikáció
Age-stratified treatment response in rheumatoid arthritis: a systematic review, meta-analysis, and integrated genetic and single-cell evidence implicating IL6R/TYK2 signaling.
2026. márc. 18.· Clinical rheumatology· PUBMED
Publikáció
TYK2 mediates neuroinflammation in Alzheimer's disease brains with TDP-43 pathology.
2026. márc. 14.· Nature communications· PUBMED
Publikáció
Deucravacitinib Inhibits Synovial Fibroblast Activation Via TYK2/STAT3 and PI3K/Akt Signaling Pathway.
2026. márc. 11.· Inflammation· PUBMED